News and ViewsWanbury's Technical Indicators Show Mixed Signals Amid Strong Long-Term Performance
2025-04-03 08:05:32Wanbury, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 251.60, having experienced fluctuations with a previous close of 268.90. Over the past year, Wanbury has shown a notable performance, with a return of 57.15%, significantly outpacing the Sensex's return of 3.67% during the same period. In terms of technical indicators, the weekly MACD suggests a mildly bullish sentiment, while the monthly perspective leans towards a mildly bearish outlook. The Bollinger Bands indicate bullish trends on both weekly and monthly scales, suggesting some positive momentum. However, moving averages present a mildly bearish stance on a daily basis, indicating mixed signals in the short term. The company's performance over various time frames highlights its resilience, particularly over the last ...
Read MoreWanbury Adjusts Valuation Grade Amidst Competitive Pharmaceuticals Landscape
2025-04-02 08:02:19Wanbury, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment, reflecting its current financial metrics and market position. The company's price-to-earnings (PE) ratio stands at 47.50, while its price-to-book value is noted at 22.74. Additionally, Wanbury's enterprise value to EBITDA ratio is 16.65, and its return on equity (ROE) is a notable 71.23%, indicating strong profitability relative to shareholder equity. In comparison to its peers, Wanbury's valuation metrics present a mixed picture. For instance, Shukra Pharma is positioned with a significantly higher PE ratio of 114.66, while Shree Ganesh Rem shows a PE of 32.21. On the other hand, Kwality Pharma and Kopran exhibit lower valuations, with PE ratios of 25.58 and 19.11, respectively. This context highlights Wanbury's competitive stance within the industry, especially considering its robust return on...
Read MoreWanbury Adjusts Valuation Grade Amid Strong Performance and Unique Market Position
2025-03-24 08:00:52Wanbury, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone a valuation adjustment. The company's current price stands at 241.70, reflecting a notable increase from the previous close of 235.00. Over the past year, Wanbury has demonstrated a strong performance with a return of 78.77%, significantly outpacing the Sensex's 5.87% return during the same period. Key financial metrics for Wanbury include a PE ratio of 42.69 and an EV to EBITDA ratio of 15.23, which position it distinctly within its industry. The company's return on equity (ROE) is particularly impressive at 71.23%, indicating effective management of shareholder equity. However, the PEG ratio remains at 0.00, suggesting a lack of growth in earnings relative to its price. In comparison to its peers, Wanbury's valuation metrics reflect a higher PE ratio than companies like Kopran and Anuh Pharma, which have lower rat...
Read MoreWanbury's Technical Indicators Signal Mixed Trends Amid Strong Yearly Performance
2025-03-20 08:03:18Wanbury, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 226.90, showing a notable increase from the previous close of 214.55. Over the past year, Wanbury has demonstrated significant resilience, with a remarkable return of 79.01%, outperforming the Sensex, which recorded a return of 4.77% in the same period. In terms of technical indicators, the weekly MACD remains bearish, while the monthly outlook is mildly bearish. The Relative Strength Index (RSI) shows no signal for both weekly and monthly assessments. Bollinger Bands indicate a mildly bearish trend on a weekly basis, contrasting with a bullish stance on a monthly scale. Daily moving averages also reflect a mildly bearish sentiment. The company's performance over various time frames highlights its volatility and potential...
Read MoreWanbury's Technical Indicators Signal Mixed Trends Amid Strong Long-Term Performance
2025-03-17 08:01:12Wanbury, a microcap player in the Pharmaceuticals & Drugs industry, has recently undergone an evaluation revision reflecting its current market dynamics. The stock is currently priced at 207.00, showing a slight increase from the previous close of 204.35. Over the past year, Wanbury has demonstrated a notable return of 54.94%, significantly outperforming the Sensex, which recorded a return of 1.47% during the same period. In terms of technical indicators, the weekly MACD is bearish, while the monthly MACD shows a mildly bearish trend. The Relative Strength Index (RSI) indicates no signal for both weekly and monthly assessments. The Bollinger Bands present a mildly bearish outlook on a weekly basis, contrasting with a bullish stance on a monthly basis. Daily moving averages also reflect a bearish sentiment. When examining the stock's performance against the Sensex, Wanbury has shown resilience over longer ...
Read MoreWanbury Ltd Shows Mixed Short-Term Performance Amid Long-Term Growth Trends
2025-03-13 18:00:37Wanbury Ltd, a microcap player in the Pharmaceuticals & Drugs industry, has shown notable stock activity today, reflecting a 1.30% increase against a backdrop of a 0.27% decline in the Sensex. The company's market capitalization stands at Rs 666.00 crore, with a price-to-earnings (P/E) ratio of 36.56, slightly above the industry average of 35.68. Over the past year, Wanbury has outperformed the Sensex significantly, achieving a remarkable 54.94% increase compared to the index's modest 1.47% gain. However, the stock has faced challenges in the short term, with a 9.31% decline over the past month and a year-to-date performance down by 28.29%, while the Sensex has decreased by 5.52% during the same period. In terms of longer-term performance, Wanbury has demonstrated substantial growth, with a 155.56% increase over the past three years and an impressive 912.22% rise over the last five years, significantly ou...
Read MoreWanbury Adjusts Valuation Amid Strong Performance and Competitive Market Landscape
2025-03-06 08:01:10Wanbury, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 191.00, reflecting a notable shift from its previous close of 173.00. Over the past year, Wanbury has demonstrated a stock return of 21.50%, significantly outperforming the Sensex, which recorded a mere 0.07% return during the same period. Key financial metrics for Wanbury include a PE ratio of 33.74 and an EV to EBITDA ratio of 12.60, indicating its market positioning within the industry. The company also boasts a strong return on equity (ROE) of 71.23% and a return on capital employed (ROCE) of 27.48%, showcasing its operational efficiency. In comparison to its peers, Wanbury's valuation metrics reveal a competitive landscape. For instance, Shree Ganesh Remedies is positioned at a higher valuation, while companies like Kopran and Anuh Pharma exhibit more ...
Read More
Wanbury Faces Financial Struggles Amid Declining Sales and High Debt Concerns
2025-03-03 18:56:26Wanbury, a microcap in the Pharmaceuticals & Drugs sector, has recently adjusted its evaluation amid a challenging financial landscape. The company reported a notable decline in net sales for Q3 FY24-25, continuing a trend of negative performance over the past three quarters, raising concerns about its growth potential.
Read MoreWanbury Adjusts Valuation Grade Amid Mixed Industry Performance and Competitive Metrics
2025-02-25 10:23:33Wanbury, a microcap player in the Pharmaceuticals & Drugs sector, has recently undergone a valuation adjustment. The company's current price stands at 198.40, slightly down from the previous close of 198.55. Over the past year, Wanbury has shown a stock return of 24.23%, significantly outperforming the Sensex, which recorded a return of 2.06% in the same period. Key financial metrics reveal a PE ratio of 34.97 and an EV to EBITDA of 12.96, indicating a competitive position within its industry. The company's return on equity (ROE) is notably high at 71.23%, reflecting strong profitability relative to shareholder equity. However, the PEG ratio remains at 0.00, suggesting a lack of growth expectations in the near term. In comparison to its peers, Wanbury's valuation metrics present a mixed picture. While it maintains a fair valuation, competitors like Shree Ganesh Rem and Shukra Pharma exhibit higher valuat...
Read More
AnnouncementFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
07-Apr-2025 | Source : BSEFormat of Initial Disclosure to be made by an entity identified as a Large Corporate.
| Sr. No. | Particulars | Details |
| 1 | Name of Company | Wanbury Ltd |
| 2 | CIN NO. | L51900MH1988PLC048455 |
| 3 | Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr) | 0.00 |
| 4 | Highest Credit Rating during the previous FY | NA |
| 4a | Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4) | Not Applicable |
| 5 | Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework | BSE |
Designation: Company Secretary and Compliance Officer
EmailId: jitendra.gandhi@wanbury.com
Designation: Chief Financial Officer
EmailId: vinod.verma@wanbury.com
Date: 07/04/2025
Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
Announcement under Regulation 30 (LODR)-Press Release / Media Release
03-Apr-2025 | Source : BSEIntimation of Improved capacity utilization for Q4 and improved margins
Announcement under Regulation 30 (LODR)-Press Release / Media Release
02-Apr-2025 | Source : BSEIntimation of schedule of Investors/ Analysts Plant Visit
Corporate ActionsCorporate Actions
No Upcoming Board Meetings
Wanbury Ltd has declared 10% dividend, ex-date: 29 Jul 10
No Splits history available
No Bonus history available
No Rights history available
